Definition

A preparation of human T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for two as of yet undisclosed tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon administration, the dual-target CAR-T cells BGT007 specifically recognize and induce selective toxicity in tumor cells expressing the two TAAs.